Fig. 1 · Structure

Documents & Downloads

Fluvastatin sodium

Cat. No. A10403 CAS 93957-55-2

HMG-CoA reductase inhibitor

Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Fluvastatin sodium Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Fluvastatin sodium from 1 published reference. In vitro models include human t-positive multiple myeloma H929 and KMS11 cells. In vivo models include female NOD/SCID mice bearing human H929 myeloma xenografts.

Fluvastatin sodium In Vitro Studies

In H929 and KMS11 myeloma cells, 4 μM fluvastatin sodium induced apoptosis and stress-response signaling. GGPP supplementation rescued these responses, whereas FPP did not, supporting involvement of the mevalonate-derived GGPP branch in these models. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

GGPP rescue of fluvastatin-induced apoptosis and stress signaling

Cell-based study · Human t(4;14)-positive multiple myeloma H929 and KMS11 cells [1]

GGPP rescued fluvastatin-induced Annexin V positivity and ATF4/CHOP/GADD34 responses; FPP did not. The rescue design supports involvement of the mevalonate-derived GGPP branch without directly measuring intracellular GGPP.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Annexin V-positive cells after 48 hQualitative rescue Rescued by 2 μM GGPP; not rescued by 10 μM FPP[1]
ATF4 protein and CHOP/GADD34 mRNA after 24 hQualitative rescue Induction rescued by GGPP, but not FPP[1]

Literature-Reported Treatment Conditions

Treatment concentration
4 μM fluvastatin; rescue conditions: 2 μM GGPP or 10 μM FPP
Exposure duration
48 h for apoptosis; 24 h for stress-response readouts
Method
Cell treatment with single-agent, rescue and metabolite-only control conditions
Vehicle
Ethanol for fluvastatin; FPP in water; GGPP supplied as ammonium-salt solution
Co-treatment
GGPP or FPP supplementation used as mechanistic rescue controls
Reported limits
Final solvent fractions and reagent enantiomeric composition not specified in the inspected methods. No exact effect sizes estimated from bars.
Methods and source locations

Compound reported in the paper: Fluvastatin sodium; Compound label in the paper: US Biological F5277-76

Model-specific literature evidence for fluvastatin sodium; no enantiomer-specific or lot-specific inference.

Figure 3A–C/caption and corresponding GGPP-rescue Results; main methods; Supplemental Materials & Methods p. 1 Reagents, pp. 1–2 assays

Annexin V-positive cells after 48 h: Annexin V flow cytometry; mean + SD, n = 3; one-way ANOVA with Bonferroni comparisons to solvent controls, *p < 0.05 as marked — Figure 3A and caption; Materials and methods: Cell viability and Annexin V assays

ATF4 protein and CHOP/GADD34 mRNA after 24 h: Immunoblotting (tubulin control) and qRT-PCR normalized to RPL13A; qRT-PCR mean + SD, n = 3 — Figure 3B–C and caption; Supplemental methods pp. 1–2

Fluvastatin sodium In Vivo Studies

In H929 xenografts, adding fluvastatin sodium to bortezomib produced greater early tumor regression than bortezomib plus vehicle. The responses approached each other by day 10, and body weight decreased in both groups. This experiment supports a model-specific combination effect. [1]

Fluvastatin addition to bortezomib in H929 xenografts

Animal study · Female NOD/SCID mice bearing human H929 myeloma xenografts [1]

Adding oral fluvastatin to bortezomib increased early tumor regression relative to bortezomib plus PBS. Both groups regressed substantially and converged toward the endpoint; both lost body weight. This comparison tests combination benefit rather than fluvastatin monotherapy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Percent change in tumor volume over 10 daysCombination versus active comparator Greater early regression with combination; *p < 0.05 at marked early comparisons[1]
Percent change in mouse body weightTolerability observation Body weight decreased in both groups; no additional overt toxicity reported by authors[1]

Conditions shared by the study groups

Treatment course
10-day observation/treatment schedule in Figure 6A
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bortezomib + PBS
Bortezomib 1 mg/kg
Active comparator for the combinationTumors regressed during treatment; serves as the active-drug comparator.[1]
Bortezomib + fluvastatin sodium
Bortezomib 1 mg/kg; fluvastatin 50 mg/kg/day
Bortezomib + PBSGreater early tumor regression than bortezomib + PBS at the marked comparisons; responses approached each other by day 10. Body weight decreased in both groups.[1]
Bortezomib + PBS
Model: 7–9-week-old female NOD/SCID mice with established subcutaneous H929 xenografts (~500 mm³ at randomization)
Route: Bortezomib intraperitoneal; PBS oral control
Frequency: Bortezomib twice weekly, three doses total
Vehicle: Bortezomib in saline; PBS comparator
Reported limits: n = 5 mice per group. Tumor assessments were not blinded. No untreated or fluvastatin-only arm in this Figure 6 experiment.
Bortezomib + fluvastatin sodium
Model: 7–9-week-old female NOD/SCID mice with established subcutaneous H929 xenografts (~500 mm³ at randomization)
Route: Bortezomib intraperitoneal; fluvastatin oral gavage
Frequency: Bortezomib twice weekly, three doses total; fluvastatin daily
Vehicle: Bortezomib in saline; fluvastatin resuspended in PBS
Reported limits: n = 5 mice per group. Tumor assessments were not blinded. No untreated or fluvastatin-only arm in this Figure 6 experiment.
Methods and source locations

Compound reported in the paper: Fluvastatin sodium; Compound label in the paper: US Biological F5277-76

Preclinical combination result in this xenograft model; no clinical efficacy, human dose conversion, enantiomer or Adooq-lot validation.

Figure 6A–C/caption and corresponding Results; Animal experiments; Supplemental reagent table p. 1

Percent change in tumor volume over 10 days: Serial tumor measurements; mean + SD; n = 5 mice/group; unpaired two-tailed Wilcoxon rank-sum test; assessments unblinded — Figure 6B and caption

Percent change in mouse body weight: Serial body-weight measurements; not a comprehensive toxicology assessment — Figure 6C; Results: Fluvastatin potentiates bortezomib activity in a t(4;14)-positive tumor model

Bortezomib + PBS · Figure 6A–C/caption; Materials and methods: Animal experiments; Supplemental reagent table p. 1

Bortezomib + fluvastatin sodium · Figure 6A–C/caption; Materials and methods: Animal experiments; Supplemental reagent table p. 1

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 93957-55-2
Applications HMG-CoA reductase inhibitor
Formula C24H25FNNaO4
Molecular Weight 433.45
Synonyms XU 62-320
SMILES
O=C([O-])C[C@H](O)C[C@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3.[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 74 mg/mL (170.72 mM)
Water 1 mg/mL (2.3 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fluvastatin sodium Research References

  1. [1] Longo J, Smirnov P, Li Z, et al. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma Leukemia (2021). PMID: 32665698 DOI: 10.1038/s41375-020-0962-2 Source material

Added to your cart

View Cart Checkout
Loading...